News | December 27, 2022
Hetero's COVID-19 oral drug gets WHO prequalification
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
The current ruling will assure the safety of the use of Ranitidine for Indian patients
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.
Pfizer’s Paxlovid is approved by US FDA for COVID treatment
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
The Congress was held on June, 20-21, 2022 in Berlin, Germany
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
Subscribe To Our Newsletter & Stay Updated
